Lexaria Bioscience (LEXX) EPS (Basic) Growth (3y) (2017 - 2026)
Lexaria Bioscience (LEXX) EPS (Basic) Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.31% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -27.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -24.54% |
| Feb 28, 2026 | -20.11% |
| Nov 30, 2025 | 35.17% |
| Aug 31, 2025 | 47.86% |
| May 31, 2025 | 45.50% |
| Feb 28, 2025 | 9.05% |
| Nov 30, 2024 | 58.17% |
| Aug 31, 2024 | 47.25% |
| May 31, 2024 | 31.22% |
| Feb 29, 2024 | 36.78% |
| Nov 30, 2023 | 37.01% |
| Aug 31, 2023 | 39.31% |
| May 31, 2023 | 40.24% |
| Feb 28, 2023 | 37.72% |
| Nov 30, 2022 | 5.00% |
| Aug 31, 2022 | 15.68% |
| May 31, 2022 | 2.83% |
| Feb 28, 2022 | 36.49% |
| Nov 30, 2021 | -8.03% |
| Aug 31, 2021 | 19.74% |